CVE-2026-108920 SourceCodester CVE debrief

Who should care

Defenders and administrators of SourceCodester Drug Recommendation System 1.0 should assess exposure and prioritize remediation due to the publicly disclosed exploit and medium CVSS score.

Why it matters

CVE-2026-108920 is a cross-site scripting vulnerability in SourceCodester Drug Recommendation System 1.0, allowing remote attackers to inject malicious scripts. Defenders should assess exposure, prioritize remediation, and verify system inventory due to the publicly disclosed exploit and medium CVSS score.

• Potential for unauthorized data exposure or manipulation
• Risk of malicious script injection and execution
• Need for inventory checks and version verification
• Priority for implementing additional security measures

Technical summary

The vulnerability exists in the user_record.php file of the Admin Record Tables feature in SourceCodester Drug Recommendation System 1.0. The issue allows remote attackers to inject malicious scripts via the name or email arguments, potentially leading to unauthorized actions or data exposure. Defenders should assess exposure, prioritize remediation, and verify system inventory due to the publicly disclosed exploit and medium CVSS score. This vulnerability has been publicly disclosed and has a medium CVSS score of 5.3, indicating a moderate level of severity. Affected product deployments should be identified in managed environments, and owners should be assigned for follow-up. Official advisories or CVE records

Defensive priority

Medium priority for inventory checks and potential remediation due to publicly disclosed exploit and medium CVSS score

Recommended defensive actions

• Inventory and version checks for Drug Recommendation System 1.0
• Review and sanitize user input in Admin Record Tables feature
• Implement additional security measures to prevent cross-site scripting
• Confirm whether affected product deployments exist in managed environments and assign an owner for follow-up
• Review the supplied official advisory or CVE record to validate affected scope, severity, and vendor guidance
• Plan vendor-supported updates or mitigations through normal change control where exposure is confirmed
• Check relevant monitoring, detection, and logs for exposed assets that need extra review

Evidence notes

The CVE record and source item provide details on the vulnerability, including its existence in version 1.0 of the Drug Recommendation System and the potential for remote exploitation. However, specific details on affected versions, exploitation, and impact are limited.

Sources and references

Methodology and review provenance

AI-assisted synthesis based on stored public vulnerability evidence. System validation, approval state, and publication status do not by themselves establish human review of this revision. PatchSiren helps prioritize defensive review and does not prove exposure or remediation on any system.